Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

Journal of medical genetics - 1 Mar 2008

Worrillow L J, Smith A G, Scott K, Andersson M, Ashcroft A J, Dores G M, Glimelius B, Holowaty E, Jackson G H, Jones G L, Lynch C F, Morgan G, Pukkala E, Scott D, Storm H H, Taylor P R, Vyberg M, Willett E, Travis L B, Allan J M

Abstract excerpt

BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers. Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system. Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to DNA Repair

Share to Hodgkin Disease

Share to Leukemia, Myeloid, Acute

Share to MutL Protein Homolog 1

Share to Neoplasms, Second Primary

Source

Open in PubMed Open full text

Identifiers

PMID: 17959715
DOI: 10.1136/jmg.2007.053850
PMCID: PMC4022773

Genes

MLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.PMID 17959715Read ↗

The association between MLH1 -93 G>A polymorphism of DNA mismatch repair and cancer susceptibility: a meta-analysis.Semantic proximity Read ↗

MLH1 polymorphisms and cancer risk: a meta-analysis based on 33 case-control studies.Semantic proximity Read ↗

Evidence for heritable predisposition to epigenetic silencing of MLH1.Semantic proximity Read ↗

Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers.Semantic proximity Read ↗

Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia.Semantic proximity Read ↗

The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.Semantic proximity Read ↗

MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer.Semantic proximity Read ↗

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.Semantic proximity Read ↗

MLH1 −93G/A Polymorphism: Its Role in Colorectal Cancer Progression and MetastasisSemantic proximity Read ↗

Effect of MLH1 -93G>A on gene expression in patients with colorectal cancer.Semantic proximity Read ↗

MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation.Semantic proximity Read ↗

A polymorphism in the hMLH1 gene (-93G-->A) associated with lung cancer susceptibility and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.